Update: Clinical progress and preparation for uplisting
Relmada continues to make progress with its emerging pain pipeline, completing a single ascending dose study and receiving clearance to commence a multiple ascending dose study for d-Methadone for neuropathic pain. It has also conducted a 1-for-5 reverse split in preparation for an uplisting to the NASDAQ by the end of 2015. We value the company at $591m or $54.68 per basic share, prior to any dilution from an estimated $110m funding requirement to profitability.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.